CClinicalTrials.gg
CompletedNCT04337710ENACTUpdated Jun 15, 2026

Exclusive Enteral Nutrition in Preterm Neonates

An interventional study of Exclusive Enteral Nutrition and Progressive Enteral Nutrition in Premature; Infant, Light-for-dates and Enteral Feeding Intolerance, sponsored by University of Alabama at Birmingham. Completed at 1 site in United States. Open to participants aged 1 Hour to 48 Hours. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
1 Hour to 48 Hours
Sex
All
01

Study summary

To test the hypothesis that early exclusive enteral nutrition with the minimal use of parenteral nutrition will improve preterm infants' nutritional outcomes when compared to delayed progression of enteral nutrition and prolonged use of parenteral nutrition.

Read the detailed description

Qualifying participants will be randomly assigned to one of two study groups: 1) Exclusive Enteral Feeds or 2) Progressive Enteral Feeds with supplemental parenteral nutrition. Regardless of study group assignment, donor human milk will be offered if the mother's expressed breast milk is not enough to complete the intervention as assigned.

Intervention group: Feeds will be initiated with a target volume of 60-80 ml/kg/day and then advanced by 20-30 ml/kg/day until the total volume of 150ml/kg/day is achieved.

Control group: Enteral feeds will be initiated with a target volume of 20-30 ml/kg/day and then advanced by 20-30 ml/kg/day until the total volume of 150 ml/kg/day is achieved.

If parent agrees, stool "dirty" diapers will be collected 2 times during this study.

One time around the time of birth and one time at 28 days or discharge (whichever occurs first).

02

Conditions studied

  • Premature; Infant, Light-for-dates
  • Enteral Feeding Intolerance

Browse trials for

03

In context

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's enrollment of 102 is above the median of 84 across 1,689 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,396 studies on the registry; 284 are open to participants now.

Of its 156 completed or terminated interventional studies of FDA-regulated products, 124 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Hour to 48 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Gestational age between 28 and 32 weeks of gestation

Exclusion criteria

Exclusion Criteria:

  • Intrauterine growth restriction (birth weight \< 10th percentile)
  • Major congenital or chromosomal anomalies
  • Terminal illness in which decisions to withhold or limit support have been made
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Exclusive Enteral Nutrition

    This group will receive enteral feeding volumes at a rate of 60-80 ml/kg/day starting within the first 24 hours after birth. Volumes will increase by 20-30 ml/kg/day until intake is 150ml/kg/day.

    Procedure: Exclusive Enteral Nutrition

  • Active comparator
    Progressive Enteral Nutrition

    This group will receive enteral feeding volumes at a rate of 20-30 ml/kg/day starting within the first 24 hours after birth. Volumes will increase by 20-30 ml/kg/day until intake is 150ml/kg/day.

    Procedure: Progressive Enteral Nutrition

Interventions

  • ProcedureExclusive Enteral Nutrition

    Mom's milk or donor milk at 60-80 ml/kg/day after randomization within the first 24 hours.

  • ProcedureProgressive Enteral Nutrition

    Mom's milk or donor milk at 20-30 ml/kg/day after randomization within the first 24 hours.

06

What researchers measure

Primary outcomes

  1. Number of days of full enteral feeding (150ml/kg/day) in the first 28 days after birth

    Days of full feeds in the first 28 days after birth

    Time frame: Birth to 28 days

Secondary outcomes

  1. Time to establish full enteral feeding

    Time interval between birth and full enteral feeding at 150ml/kg/day

    Time frame: Birth to 28 days

  2. Number of episodes of feeding intolerance

    Interruption or cessation of enteral feeds for a period greater than 12 hours for abnormal abdominal examination

    Time frame: Birth to 28 days

  3. Number of days receiving parenteral nutrition and IV fluids

    Time frame: Birth to 28 days

  4. Number of days receiving central line access

    Time frame: Birth to 28 days

  5. Number of episodes of culture proven sepsis

    Positive blood cultures

    Time frame: Birth to 60 days or discharge, whichever occurs first

  6. Number of participants with diagnosis of necrotizing enterocolitis

    Diagnosis of necrotizing enterocolitis stage 2 or 3

    Time frame: Birth to 60 days or discharge, whichever occurs first

  7. Number of participants with diagnosis of intestinal perforation

    Pneumoperitoneum on abdominal radiograph

    Time frame: Birth to 14 days

  8. Death

    Time frame: Birth to 60 days

  9. Weight

    Weekly measurements of weight in g

    Time frame: Birth to 60 days

  10. Length

    Weekly measurements of length in cm

    Time frame: Birth to 60 days

  11. Head circumference

    Weekly measurements of head circumference in cm

    Time frame: Birth to 60 days

  12. Duration of hospital stay in days

    Time frame: Birth to 60 days

Other outcomes

  1. Intestinal microbiome profile

    Determined by molecular analyses of bacterial fragments in fecal samples

    Time frame: At postnatal day 14

  2. Fat-free mass z score

    Determined by air-displacement plethysmography

    Time frame: At postnatal day 14

07

Study locations

1 site
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
08

References and documents

Publications

  • Salas AA, Stewart CJ, Young GR. Early gut microbiome composition of very preterm infants randomised to receive human milk volumes of 60 ml/kg/day or more within the first 36 hours after birth. Pediatr Res. 2026 Jun;99(5):1964-1969. doi: 10.1038/s41390-025-04456-5. Epub 2025 Oct 2. PubMed 41034647 ↗
  • Razzaghy J, Shukla VV, Gunawan E, Reeves A, Nguyen K, Salas AA. Early and exclusive enteral nutrition in infants born very preterm. Arch Dis Child Fetal Neonatal Ed. 2024 Jun 19;109(4):378-383. doi: 10.1136/archdischild-2023-325969. PubMed 38135494 ↗

Related links

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04337710
Lead sponsor
University of Alabama at Birmingham
Responsible party
Ariel A. Salas (Assistant Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Apr 8, 2020
Start date
May 27, 2021
Primary completion
Sep 12, 2022
Completion
Sep 15, 2025
Last update
Jun 15, 2026

Study contacts

Vivek Shukla, MD
study chair · University of Alabama at Birmingham
Ariel Salas, MD, MSPH
study director · University of Alabama at Birmingham
Jacqueline Razzaghy, MD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion